Euroopan unioni - viro - EMA (European Medicines Agency)

vbi vaccines b.v. - hepatiit b pinnaantigeen - b-hepatiit - vaktsiinid - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Viro - viro - Ravimiamet

glaxosmithkline eesti oÜ - leetrite tekitaja, elus, nõrgestatud+mumpsiviirus, elus, nõrgestatud+punetiste tekitaja, elus, nõrgestatud+tuulerõugete viirus, elus, nõrgestatud - süstelahuse pulber ja lahusti - 100tk; 10tk; 1tk

Viro - viro - Ravimiamet

glaxosmithkline biologicals - leetrite tekitaja, elus, nõrgestatud+mumpsiviirus, elus, nõrgestatud+punetiste tekitaja, elus, nõrgestatud+tuulerõugete viirus, elus, nõrgestatud - süstelahuse pulber ja lahusti süstlis - 1tk; 20tk; 50tk; 10tk

Viro - viro - Ravimiamet

sanofi pasteur s.a. - difteeria-teetanus-läkaköha - süstesuspensioon - 0.5ml 10tk; 0.5ml 1tk

Euroopan unioni - viro - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant modified vaccinia ankara bavarian nordic virus encoding the: ebola virus zaire (zebov) mayinga strain glycoprotein (gp); ebola virus sudan gulu strain gp; ebola virus taï forest strain nucleoprotein and the marburg virus musoke strain gp - hemorraagiline palavik, ebola - vaktsiinid - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Euroopan unioni - viro - EMA (European Medicines Agency)

dynavax gmbh - hepatiit b pinnaantigeen - b-hepatiit - vaktsiinid - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Euroopan unioni - viro - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumokoki infektsioonid - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age. vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. vt lõigud 4. 4 ja 5. 1, mis käsitleb kaitset spetsiifiliste pneumokokkide serotüüpide eest. the use of vaxneuvance should be in accordance with official recommendations.

Euroopan unioni - viro - EMA (European Medicines Agency)

janssen-cilag international n.v.    - recombinant adenovirus type 26 (ad26) encoding the glycoprotein (gp) of the ebola virus zaire (zebov) mayinga strain - hemorraagiline palavik, ebola - vaktsiinid - active immunization for prevention of disease caused by ebola virus (zaire ebolavirus species) in individuals ≥ 1 year of age.

Viro - viro - Ravimiamet

medochemie limited - itopriid - õhukese polümeerikattega tablett - 50mg 40tk; 50mg 100tk; 50mg 30tk

Viro - viro - Ravimiamet

medochemie limited - itopriid - õhukese polümeerikattega tablett - 50mg 20tk; 50mg 100tk; 50mg 30tk